Navigation Links
Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
Date:2/12/2013

RARITAN, N.J., Feb. 12, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen), today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designations for the investigational oral agent ibrutinib as a monotherapy for two B-cell malignancies: in patients with relapsed or refractory mantle cell lymphoma (MCL) who have received prior therapy, and in patients with Waldenstrom's macroglobulinemia (WM).

Enacted as part of the 2012 FDA Safety and Innovation Act (FDASIA), Breakthrough Therapy Designation is intended to expedite the development and review time for a potential new medicine "to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development."[1]

"We are pleased that the FDA has granted two Breakthrough Therapy Designations for ibrutinib as the designation represents a major leap forward in accelerating drug development timelines," said Paul Stoffels , M.D., Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals, Johnson & Johnson. "We are committed to realizing the full potential of ibrutinib for patients with mantle cell lymphoma, Waldenstrom's macroglobulinemia, as well as other B-cell malignancies, and will work with Pharmacyclics and the FDA to ensure the clinical development program for ibrutinib continues to move forward as quickly as possible."

Janssen Biotech, Inc. and Pharmacyclics entered a collaboration and license agreement in December 2011 to co-develop and co-commercialize ibrutinib. T
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
2. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
3. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
4. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
5. Remique (TM), a Revolutionary Dietary Supplement, Manufactured in FDA Registered Facilities, Receives Raves from Compromised Immune System Sufferers
6. Life Technologies Receives FDA 510(k) Clearance for Diagnostic Use of Sanger Sequencing Platform and HLA Typing Kits
7. Rafarma Pharmaceuticals, Inc. Receives General License for Pharmaceutical Products and has Started to Manufacture 3 New Products
8. Morphotek Inc. Pilot Plant Receives 2013 Facility of the Year Award
9. Arteriocyte Receives FDA Approval to Initiate Cellular Therapy Trial for Treatment of Thermal Burn Wounds in Wounded Warriors
10. Virtual Ports Receives Patent Approvals in the United States and Japan
11. CytoSorbents Receives Approximately $400,000 in Non-Dilutive Capital from the Sale of Net Operating Loss Carryovers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 18, 2013 /PRNewswire-iReach/ -- Today E-T-A ... X3130 Appliance Inlet Module. The X3130, integrated with ... combines a C14 appliance inlet module, rocker switch ... This three-in-one device allows design engineers to streamline ... cutting installation time by 66 percent - and ...
(Date:6/18/2013)... -- Royal Philips (NYSE: PHG, AEX: PHIA) ... in Imaging Equipment in the 2013 Best in KLAS ... Best in KLAS and Best in Category awards for ... Computed Tomography (CT), Ingenia 1.5T and 3.0T Magnetic Resonance ... Best in KLAS Awards: Medical Imaging & Infrastructure are ...
(Date:6/18/2013)... , June 18, 2013 Unilife Corporation ... based designer, developer and manufacturer of injectable drug delivery ... website at www.unilife.com . The new site includes ... updates to occur on a regular basis. ... stated, "As an emerging global leader for injectable drug ...
Breaking Medicine Technology:Three-in-One X3130 Appliance Inlet Module 2Philips Named 2013 Overall Performance Leader In Imaging Equipment By KLAS 2Unilife Launches New Corporate Website 2
... Incorporated (Nasdaq: ARAY ), a global ... Senior Vice President, General Counsel and Corporate Secretary, Darren ... by the Silicon Valley/San Jose Business Journal and ... their ,Best Bay Area Corporate Counsel Awards,. This annual awards ...
... 25, 2011 Landauer, Inc. (NYSE: LDR ... quarterly cash dividend of $0.55 per share for the second quarter ... 2011, to shareholders of record on March 11, 2011. ... provider of technical and analytical services to determine occupational and environmental ...
Cached Medicine Technology:Accuray's General Counsel Wins Best Bay Area Corporate Counsel Award 2Accuray's General Counsel Wins Best Bay Area Corporate Counsel Award 3Accuray's General Counsel Wins Best Bay Area Corporate Counsel Award 4
(Date:6/19/2013)... percent of Americans are on at least one ... Mayo Clinic researchers say. Antibiotics, antidepressants and painkilling ... Twenty percent of patients are on five or ... online in the journal Mayo Clinic Proceedings ... of Dr. Jennifer St. Sauver talking about the ...
(Date:6/19/2013)... June 19, 2013 North Carolina-based ... organizational changes to advance development of its technologies. ... “To support the advanced development of our product ... to the Company’s management structure and engaged industry ... Company announced that Michael Galiger will serve as ...
(Date:6/19/2013)... Ga (PRWEB) June 19, 2013 Brightree ... and business management software solutions for the post-acute care industry, ... 79 - on the Healthcare Informatics 100 (HCI 100) ... IT companies in the U.S. in terms of revenue during ... at an average rate of 85% annually, and the company ...
(Date:6/19/2013)... Many trying-to-conceive couples seek medical intervention ... to a recent study published in ... of this research confirm what Fairhaven Health has ... that trying-to-conceive women would benefit from tracking ovulation, ... Fairhaven Health is a leading provider of ovulation ...
(Date:6/19/2013)... to the brink of extinction but can we finish ... which a Bristol academic addresses in his new book, published ... the University of Bristol, has produced the first comprehensive history ... story of polio explores the experiences of victims alongside the ... , According to a review by The ...
Breaking Medicine News(10 mins):Health News:Nearly 7 in 10 Americans are on prescription drugs, Mayo Clinic study finds 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 3Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 2Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 4Health News:Paralysed with fear: The story of polio 2
... devastating brain injury that has wiped out many of ... other peoples feelings and intentions, according to a joint ... Centre for Aging and the Brain, and York Universitys ... published in the Nov. 23, 2007 issue of Science, ...
... sleepiness, experts say, , , THURSDAY, Nov. 22 (HealthDay News) ... Thanksgiving feast aren,t rare, and experts say a number ... , It may have to do with the traditional ... a chemical known to promote sleepiness, said Donna Arand, ...
... future treatment of breast cancer have been identified by a ... the online open access journal Breast Cancer Research may focus ... , A team led by Professor Mitch Dowsett, Head of ... London and Surrey, together with colleagues from the USA, Switzerland ...
... CHICAGO, Nov. 21 The Female Health Company,(Amex: ... The Wall Street,Analyst Forum 18th Annual Analyst Conference on ... York City (on 43rd Street between 5th and,6th). The ... will,present at the conference at 11:50 a.m. Eastern Time ...
... mean more ozone, and more strain on hearts, researchers ... temperatures and high ozone levels work together to boost ... , They believe that global warming -- which brings ... the number of people who die of cardiovascular events. ...
... PICK: Pregnant women pass on the effects of smoking ... effects on fetal development. A new study in mice ... Toronto, Canada, now adds the possibility that smoking before ... of female offspring to the long list of possible ...
Cached Medicine News:Health News:People with rare type of memory loss still sensitive to others, study shows 2Health News:People with rare type of memory loss still sensitive to others, study shows 3Health News:There's More Than Turkey Behind Holiday Yawns 2Health News:Found in translation: Prioritizing research questions in breast cancer 2Health News:The Female Health Company to Present at Wall Street Analyst Forum Wednesday, November 28, 2007 2Health News:Global Warming May Trigger Rise in Heart Deaths 2Health News:Global Warming May Trigger Rise in Heart Deaths 3Health News:JCI table of contents: Nov. 21, 2007 2Health News:JCI table of contents: Nov. 21, 2007 3Health News:JCI table of contents: Nov. 21, 2007 4Health News:JCI table of contents: Nov. 21, 2007 5Health News:JCI table of contents: Nov. 21, 2007 6Health News:JCI table of contents: Nov. 21, 2007 7Health News:JCI table of contents: Nov. 21, 2007 8Health News:JCI table of contents: Nov. 21, 2007 9Health News:JCI table of contents: Nov. 21, 2007 10
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: